Jones Lang LaSalle Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Jones Lang LaSalle Inc trades at $303.6 (market cap $13.65B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: Jones Lang LaSalle Inc is far larger — about 6× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals.
| JLL | SLS | |
|---|---|---|
Market Cap | $13.65B | $2.28B |
Volume | 465,758 | 3,128,960 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $15.46 |
52-Week Low | $280.16 | $1.39 |
Typical Hold Time | 71 Days | — |
Enterprise Value | $16.41B | $2.15B |
Signals from Pluang's Aura AI — not financial advice
JLL trades at $296.66, down 2.29% today, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $5.26 beating expectations by 15%. Revenue growth accelerated to $26.12 billion in 2025, while net income margin improved to 3.64%. Recent acquisitions and financing deals demonstrate continued expansion in key markets.
The stock presents a compelling value opportunity with a P/E of 14.23 and P/S of 0.52 below industry averages. Analyst consensus targets $450.50, implying 52% upside potential. Key risks include real estate market cyclicality and execution challenges in global expansion. Strong cash flow generation and institutional buying support the bullish fundamental case despite near-term technical weakness.
No Aura AI signal available yet.
Trailing returns across standard periods
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →